SC Filed 2019-04-24 Event — SEC 0001144204-19-020958 →

RA CAPITAL MANAGEMENT, LLC → KalVista Pharmaceuticals, Inc. KALV

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 11/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Filer track record (20 filings): 0% 90d win rate, +0.0% 90d edge
Held by 1 tracked 13F institutional manager

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

7 transactions

0 buys · 3 sales · 4 awards/exercises

Issuer Cluster

10 13D/G filings on this issuer

9 other filings besides this one

Filer Track Record

88 filings by this filer

87 other filings in the data moat

Short Interest · settle 2026-05-29

DTC 1.97

6,842,479 shares short · -43.2% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $36.88M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-17	Palleiko Benjamin L	director, officer	Sale	9,550	$20.22	$193K
2026-04-17	Piekos Brian	officer	Sale	1,862	$20.22	$38K
2026-04-17	Sweeny Nicole	officer	Sale	1,862	$20.22	$38K
2026-04-16	Piekos Brian	officer	Option exercise	6,250	—	—
2026-04-16	Audhya Paul K.	officer	Option exercise	6,250	—	—
2026-04-16	Sweeny Nicole	officer	Option exercise	6,250	—	—
2026-04-16	Palleiko Benjamin L	director, officer	Option exercise	20,312	—	—

Other 13D/G Filings on KalVista Pharmaceuticals, Inc.

Filed	Form	Filer	Stake	Shares
2026-06-10	SCHEDULE 13G	GLAZER CAPITAL, LLC	—	—	view →
2026-05-21	SCHEDULE 13D/A	Frazier Life Sciences Public Fund, L.P.	2.30%	1,249,165	view →
2024-04-01	SC	TCG Crossover GP I, LLC	—	—	view →
2024-02-20	SC	TCG Crossover GP I, LLC	—	—	view →
2022-02-10	SC	Longwood Fund II, L.P.	—	—	view →
2021-02-16	SC	SVLSF IV, LLC	—	—	view →
2019-04-15	SC	RA CAPITAL MANAGEMENT, LLC	—	—	view →
2019-04-03	SC	SVLSF IV, LLC	—	—	view →
2019-03-20	SC	SVLSF IV, LLC	—	—	view →

Other Filings by RA CAPITAL MANAGEMENT, LLC

Filed	Form	Issuer	Stake	Shares
2026-10-26	SCHEDULE 13G	Alector, Inc.	—	—	view →
2026-10-22	SCHEDULE 13G	Frazier Life Sciences Acquisition Corp. II	—	—	view →
2026-09-22	SCHEDULE 13G	BetterLife Pharma Inc.	—	—	view →
2026-09-21	SCHEDULE 13D/A	SIONNA THERAPEUTICS, INC.	14.30%	6,476,193	view →
2026-09-17	SCHEDULE 13D/A	TYRA BIOSCIENCES, INC.	—	14,130,492	view →
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →

Showing 20 of 87

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →